|
EP1392345B2
(en)
|
2001-05-25 |
2018-02-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
|
|
EP4091624A1
(en)
|
2013-03-15 |
2022-11-23 |
Protagonist Therapeutics, Inc. |
Hepcidin analogues and uses thereof
|
|
WO2019018377A1
(en)
*
|
2017-07-18 |
2019-01-24 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
DISULFIDE-MASKED PRO-CHELATE COMPOSITIONS AND METHODS OF USE
|
|
US11504346B2
(en)
|
2013-11-03 |
2022-11-22 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redox-activated pro-chelators
|
|
US12383518B2
(en)
|
2013-11-03 |
2025-08-12 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
HRP20211448T1
(hr)
|
2014-05-16 |
2021-12-24 |
Protagonist Therapeutics, Inc. |
Alfa4beta7 integrin tioeter peptidni antagonisti
|
|
CN107206254B
(zh)
|
2014-07-17 |
2021-08-24 |
领导医疗有限公司 |
白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
|
|
WO2016054411A1
(en)
|
2014-10-01 |
2016-04-07 |
Protagonist Therapeutics, Inc. |
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
US10301371B2
(en)
|
2014-10-01 |
2019-05-28 |
Protagonist Therapeutics, Inc. |
Cyclic monomer and dimer peptides having integrin antagonist activity
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20190002503A1
(en)
*
|
2015-12-30 |
2019-01-03 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
EP3399996A4
(en)
*
|
2016-01-08 |
2019-10-16 |
La Jolla Pharmaceutical Company |
METHOD FOR THE ADMINISTRATION OF HEPCIDINE
|
|
CA3017926C
(en)
|
2016-03-23 |
2023-10-10 |
Protagonist Therapeutics, Inc. |
Methods for synthesizing .alpha.4.beta.7 peptide antagonists
|
|
EP3509621A4
(en)
*
|
2016-09-06 |
2020-06-17 |
La Jolla Pharmaceutical Company |
METHODS OF TREATING IRON OVERLOAD
|
|
BR112019012257A2
(pt)
*
|
2016-12-19 |
2019-12-10 |
La Jolla Pharmaceutical Company |
métodos de administração de hepcidina
|
|
WO2018128828A1
(en)
|
2016-12-23 |
2018-07-12 |
Bayer Healthcare Llc |
Novel hepcidin mimetics and uses thereof
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
CA3089868A1
(en)
|
2018-02-08 |
2019-08-15 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
WO2020014646A1
(en)
|
2018-07-12 |
2020-01-16 |
Protagonist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US11286243B2
(en)
|
2018-12-13 |
2022-03-29 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
|
MX2021013616A
(es)
|
2019-05-07 |
2021-12-10 |
Bayer Ag |
Compuestos inhibidores de la masp y usos de estos.
|
|
JP7534382B2
(ja)
|
2019-07-10 |
2024-08-14 |
プロタゴニスト セラピューティクス， インコーポレイテッド |
インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
|
|
PH12022550510A1
(en)
*
|
2019-09-03 |
2023-09-04 |
Protagonist Therapeutics Inc |
Conjugated hepcidin mimetics
|
|
EP4041243A4
(en)
*
|
2019-09-27 |
2023-10-18 |
Disc Medicine, Inc. |
METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE
|
|
US20220372135A1
(en)
*
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating myelofibrosis and related conditions
|
|
CA3167751A1
(en)
|
2020-01-15 |
2021-07-22 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
AU2021209086A1
(en)
|
2020-01-15 |
2022-08-04 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20230226074A1
(en)
|
2020-04-28 |
2023-07-20 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
|
CA3181577A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
|
KR20230007441A
(ko)
|
2020-04-28 |
2023-01-12 |
글로벌 블러드 테라퓨틱스, 인크. |
페로포르틴 억제제로서의 시클로알킬 피리미딘
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
CN111560051B
(zh)
*
|
2020-05-26 |
2022-11-25 |
大连工业大学 |
一种具有促铁吸收活性的虾源九肽及其应用
|
|
WO2022003238A1
(en)
*
|
2020-07-02 |
2022-01-06 |
Tampere University Foundation Sr |
Renin-based analysis of hepcidin
|
|
AU2021315564A1
(en)
*
|
2020-07-28 |
2023-02-09 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CN114252627A
(zh)
*
|
2020-09-24 |
2022-03-29 |
首都医科大学附属北京世纪坛医院 |
尿液铁调素及其多肽片段在过敏性疾病中的应用
|
|
JP7397239B2
(ja)
|
2020-11-20 |
2023-12-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
インターロイキン－２３受容体のペプチド阻害剤の組成物
|
|
AU2022249095A1
(en)
*
|
2021-04-01 |
2023-10-12 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
IL309166A
(en)
*
|
2021-06-14 |
2024-02-01 |
Protagonist Therapeutics Inc |
Pasidine mimesis for the treatment of hereditary hemochromatosis
|
|
EP4370146A4
(en)
|
2021-07-14 |
2025-05-21 |
Janssen Biotech, Inc. |
Lipidated peptide inhibitors of the interleukin-23 receptor
|
|
CN115703826B
(zh)
*
|
2021-08-03 |
2025-05-06 |
浙江大学 |
铁调素改造体及其应用
|
|
WO2024059264A1
(en)
*
|
2022-09-15 |
2024-03-21 |
Migal Galilee Research Institute Ltd |
Site-specific activation of regulatory t cells
|
|
WO2025224128A1
(en)
|
2024-04-24 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut
|